Other languages Circio Holding ASA

Equities

TRVX

NO0013033795

Real-time Oslo Bors Other stock markets 05:24:28 2024-05-07 EDT			5-day change	1st Jan Change
2.35 ^NOK	+0.43%		-6.00%	-67.36%

04-25	Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-17	Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023	04-25
Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus	04-17
Circio Holding ASA Terminates TG01 Cancer Vaccine License Option Agreement with IOVaxis therapeutics in China for Non-Payment	04-17
Circio Partner Exercises Option to License Cancer Vaccine in China	03-19
Circio Holding ASA Announces Partner IOVaxis Therapeutics Exercises the Option for an Exclusive License to Mutant RAS Cancer Vaccine TG01 in China	03-19
Atlas Special Opportunities Converts Circio's Convertible Bonds to Shares	02-05
Circio Doses First Patient in Phase 2 Trial of Cancer Vaccine	02-01
Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University	02-01
Circio Gets Approval for EUR6 Million Loans Waiver for Tumor Cell Technology Development	01-18
Atlas Special Opportunities Converts NOK1 Million of Circio Convertible Bonds	01-10
Circio Partner Files Investigational New Drug Application for Cancer Vaccine in China	12-12
IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration	12-12
Circio to Begin Clinical Trial for Blood Cancer Vaccine After Successful Safety Review	12-07
Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital	12-07
Circio Joins Collaboration to Test the Combination of TG01 Vaccination with Daratumumab and Nivolumab in Immunotherapy-Resistant Patients with Mutant RAS Cancers	11-16
Georgetown University-led Collaboration to Test Circio's Drug Candidate Against RAS-mutated Cancers	11-16
Circio Holding ASA Announces Management Changes	23-10-18
Circio Holding ASA and Neoregen Biotech Enter Collaboration for Delivery of Novel Circular Rna Therapeutics Using Nict Technology	23-10-10
Circio Holding Asa Announces Oncos-102 Mesothelioma Study Published in Journal for Immunotherapy of Cancer	23-09-03
Circio Holding ASA Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Circio Holding ASA

Equities

TRVX

NO0013033795

Other languages

Filters